Novo Nordisk A/S
NOVO-B
Ранг среди акций
#107
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Цена акции
$39.74
Рыночная капитализация
$175.38B
Изменение (1 день)
1.28%
Изменение (1 год)
-25.58%
Страна
DK
Торговля Novo Nordisk A/S (NOVO-B)
Категория
Healthcare
Выручка компании Novo Nordisk A/S (NOVO-B)
Выручка на Jun 2026 TTM: $49.50B
Согласно последним финансовым отчетам Novo Nordisk A/S, текущая выручка компании (TTM) составляет $49.50B. В 2024 году компания получила выручку $40.52B больше, чем выручке в 2023 году, которая составила $34.39B. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки Novo Nordisk A/S с 2001 по 2026
Выручка на конец каждого года
| Год | Выручка | Изменить |
|---|---|---|
| 2026 (TTM) | $49.50B | 1.95% |
| 2025 | $48.55B | 19.82% |
| 2024 | $40.52B | 17.82% |
| 2023 | $34.39B | 35.02% |
| 2022 | $25.47B | 18.29% |
| 2021 | $21.53B | 3.33% |
| 2020 | $20.84B | 13.79% |
| 2019 | $18.31B | 6.63% |
| 2018 | $17.17B | -4.59% |
| 2017 | $18.00B | 13.46% |
| 2016 | $15.86B | 0.88% |
| 2015 | $15.73B | 8.89% |
| 2014 | $14.44B | -6.28% |
| 2013 | $15.41B | 11.69% |
| 2012 | $13.80B | 19.42% |
| 2011 | $11.55B | 6.01% |
| 2010 | $10.90B | 10.52% |
| 2009 | $9.86B | 15.53% |
| 2008 | $8.54B | 3.65% |
| 2007 | $8.24B | 20.44% |
| 2006 | $6.84B | 28.15% |
| 2005 | $5.34B | -0.14% |
| 2004 | $5.34B | 18.51% |
| 2003 | $4.51B | 27.01% |
| 2002 | $3.55B | 25.45% |
| 2001 | $2.83B | 0.00% |
Выручка аналогичных компаний или конкурентов
| Компания | Выручка | Разница в выручке | Страна |
|---|---|---|---|
| $79.67B | 60.96% |
US
|
|
| $99.34B | 100.70% |
US
|
|
| $64.39B | 30.08% |
US
|
|
| $66.40B | 34.15% |
US
|
|
| $73.95B | 49.40% |
CH
|
